HR and 95% CI of subjects with newly diagnosed type 2 diabetes by quartiles of FPG variability
| Events (n) | Follow-up duration (person-years) | Incidence rate (per 1,000 person-years) | Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| FPG variability (FPG-CV) | |||||||||
| Q1 | 2,083 | 264,236 | 7.88 | 1 | 1 | 1 | |||
| Q2 | 2,071 | 263,962 | 7.85 | 1.00 (0.94–1.06) | 0.9121 | 1.03 (0.97–1.10) | 0.3082 | 1.09 (1.03–1.16) | 0.0047 |
| Q3 | 2,303 | 263,039 | 8.76 | 1.11 (1.05–1.18) | 0.0004 | 1.14 (1.07–1.21) | <0.0001 | 1.30 (1.22–1.38) | <0.0001 |
| Q4 | 2,846 | 259,685 | 10.96 | 1.39 (1.32–1.47) | <0.0001 | 1.37 (1.30–1.45) | <0.0001 | 1.67 (1.58–1.77) | <0.0001 |
| P for trend | <0.0001 | <0.0001 | <0.0001 | ||||||
| FPG variability (FPG-SD) | |||||||||
| Q1 | 1,770 | 265,631 | 6.66 | 1 | 1 | 1 | |||
| Q2 | 1,913 | 264,698 | 7.23 | 1.09 (1.02–1.16) | 0.0119 | 1.13 (1.06–1.20) | 0.0003 | 1.08 (1.01–1.15) | 0.0220 |
| Q3 | 2,367 | 262,534 | 9.02 | 1.36 (1.28–1.44) | <0.0001 | 1.39 (1.30–1.47) | <0.0001 | 1.29 (1.21–1.37) | <0.0001 |
| Q4 | 3,253 | 258,058 | 12.61 | 1.90 (1.79–2.01) | <0.0001 | 1.85 (1.75–1.97) | <0.0001 | 1.63 (1.54–1.73) | <0.0001 |
| P for trend | <0.0001 | <0.0001 | <0.0001 | ||||||
| FPG variability (FPG-VIM) | |||||||||
| Q1 | 1,920 | 264,952 | 7.25 | 1 | 1 | 1 | |||
| Q2 | 2,000 | 264,292 | 7.57 | 1.05 (0.98–1.11) | 0.1606 | 1.08 (1.02–1.15) | 0.0125 | 1.10 (1.03–1.17) | 0.0040 |
| Q3 | 2,332 | 262,817 | 8.87 | 1.23 (1.16–1.30) | <0.0001 | 1.25 (1.18–1.33) | <0.0001 | 1.28 (1.21–1.36) | <0.0001 |
| Q4 | 3,051 | 258,860 | 11.79 | 1.63 (1.54–1.73) | <0.0001 | 1.60 (1.51–1.69) | <0.0001 | 1.65 (1.56–1.75) | <0.0001 |
| P for trend | <0.0001 | <0.0001 | <0.0001 | ||||||
Model 1, adjusted for age and sex. Model 2, adjusted for age, sex, BMI, alcohol consumption, smoking, regular exercise, income, family history of diabetes, hypertension, dyslipidemia, and mean FPG. Q, quartile.